Lantheus Receives FDA Tentative Approval for PNT2003 Lu-177 Radioequivalent Therapy

Lantheus Holdings, Inc. announced that the U.S. Food and Drug Administration granted tentative approval for its Abbreviated New Drug Application for Lutetium Lu 177 Dotatate (PNT2003), the company said in a March 2 press release distributed via Globe Newswire. The filing identifies PNT2003 as a radioequivalent1 version of LUTATHERA® and targets adults with somatostatin receptor‑positive gastroenteropancreatic neuroendocrine tumors, including foregut, midgut, and hindgut NETs. Lantheus is headquartered in Bedford, Massachusetts and trades on NASDAQ under the ticker LNTH.

Mary Anne Heino, chief executive officer of Lantheus, framed the milestone in patient access and diagnostics: “As the first radioequivalent to LUTATHERA to receive FDA tentative approval, PNT2003 marks an important step forward in Lantheus’ work to advance treatment options for patients with GEP‑NETs. This milestone comes at a time when advances in imaging and evolving clinical guidelines are enabling the identification of more patients who stand to benefit from targeted radiopharmaceutical therapies. As the leading radiopharmaceutical‑focused company, we remain committed to meeting this growing demand and look forward to making PNT2003 available to patients pending final FDA approval,” Heino said in the company release.

Industry coverage emphasized the regulatory implications. RadiologyBusiness noted that “the drug’s tentative approval suggests it has met the FDA’s requirements for approval under the Federal Food, Drug and Cosmetics Act,” and reported that “full approval is expected to come through by June of this year,” an expectation the press coverage linked to market timing rather than a company statement. Scout, an oncology knowledge service, summarized the action as: “The FDA tentatively approved PNT2003 (lutetium Lu 177 dotatate), a radioequivalent version of lutetium Lu 177 dotatate (Lutathera) ... based on comparable efficacy and safety data.”

Clinical context for the reference product remains the NETTER‑1 phase 3 trial (NCT01578239), which CancerNetwork cites as the primary evidence for LUTATHERA®’s initial approval: the NETTER‑1 comparison of lutetium Lu 177 dotatate plus octreotide versus octreotide alone showed a progression‑free survival hazard ratio of 0.21 (95% CI 0.13–0.32), with median PFS not reached in the lutetium arm versus 8.5 months for the control at primary analysis.

RadiologyBusiness also identified Advanced Accelerator Applications, a Novartis company, as the manufacturer of LUTATHERA®, a detail not included in Lantheus’ announcement. The Lantheus press release does not specify where PNT2003 will be manufactured or detail the bridging or bioequivalence studies underlying the ANDA; those data were not included in the materials distributed via Globe Newswire.

Tentative approval preserves the pathway to final FDA sign off; Lantheus says it looks forward to making PNT2003 available pending that final approval. If full approval follows, PNT2003 would introduce an additional radiopharmaceutical option against a backdrop of rising GEP‑NET incidence and increased detection from improved imaging and updated clinical guidelines, potentially affecting supply options currently tied to LUTATHERA® production.